NeuroVive: Interim Report 1 Jan. 2013 till 30 Sep. 2013

Increased interest in NeuroVives product portfolio with cyclophilin inhibitors
and energy regulators
This Interim Report is published in Swedish and English. In the event of any
difference between the English version and the Swedish original, the Swedish
version shall prevail.

Increased interest in NeuroVives product portfolio with cyclophilin inhibitors
and energy regulators

Nine months (1 Jan. 2013 – 30 Sep. 2013)

  · Net revenues were SEK 5,335,000 (0) and other operating income was SEK
1,586,000 (520,000).
  · Loss before tax was SEK -12,957,000 (-10,755,000).
  · Earnings per share* were SEK -0.72 (-0.60).
  · Diluted earnings per share** were SEK -0.72 (-0.60).

Third quarter (1 Jul. 2013 – 30 Sep. 2013)

  · Net revenues were SEK 0 (0) and other operating income was SEK 723,000
(201,000).
  · Loss before tax was SEK -6,751,000 (-3,884,000).
  · Earnings per share* were SEK -0.33 (-0.19).
  · Diluted earnings per share** were SEK-0.33 (-0.19).

* Profit/loss for the period divided by the average number of shares before
dilution at the end of the period.
**Profit/loss for the period divided by the average number of shares after
dilution at the end of the period.

Business highlights in the third quarter of 2013

  · Over 800 of the 972 patients have been enrolled in the multinational phase
III trial on the company’s pharmaceuticals CicloMulsion® (CIRCUS trial) to treat
reperfusion injury coincident with myocardial infarction.
  · With its collaboration partner Sihuan, NeuroVive participated in the 18th
Army Neurosurgery Annual Conference in Beijing, China.

Post balance sheet events

  · NeuroVive has appointed Catharina Jz Johansson as its new CFO. She will take
up her position on 1 December 2013.
  · NeuroVive proposes resolution on private placement and rights issue totaling
approximately SEK 111 m.
  · NeuroVive has announced that an extraordinary General Meeting will be held
on Friday 13thDecember at 10 am in Lund.

Read the interim report attached below

NeuroVive Pharmaceutical AB (publ) is obligated to publish the information
contained in this press release in accordance with the Swedish Securities Market
Act. This information was provided to the media for publication at 18:00 CEST on
November 20, 2013.